Madrigal Pharmaceuticals, Inc. (BIT:1MDGL)
288.00
-13.70 (-4.54%)
At close: May 2, 2025
Madrigal Pharmaceuticals Company Description
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc.
Country | United States |
Industry | Pharmaceutical Preparations |
Employees | 528 |
CEO | William Sibold |
Contact Details
Address: Four Tower Bridge West Conshohocken, Delaware 19428 United States | |
Phone | 267 824 2827 |
Website | madrigalpharma.com |
Stock Details
Ticker Symbol | 1MDGL |
Exchange | Borsa Italiana |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
William Sibold | Chief Executive Officer |
Mardi Dier | Chief Financial Officer |
Mark Underwood | Chief Operating Officer |
Tina Ventura | Head of Investor Relations |